SEC Form 4 · accession 0001209191-18-007561
Conatus Pharmaceuticals Inc. · CNAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel L. Ripley
Officer — SVP, Bus Dev, P&A Mgmt
Period of report
Feb 4, 2018
Accepted (ET)
Feb 5, 2018 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001383701
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | May 12, 2017 | A | 761 | $1.70 | A | 28,462 | I | See footnote. |
| Common StockF4,F3 | Nov 14, 2017 | A | 818 | $3.48 | A | 29,280 | I | See footnote. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $5.17 | Feb 4, 2018 | A | 40,000 | A | — | Feb 3, 2028 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1These shares were acquired under the Company's 2013 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2In accordance with the Company's 2013 Employee Stock Purchase Plan, these shares were purchased based on 85% of the closing price of the Issuer's common stock on November 15, 2016, which was the first trading day of the applicable offering period.
- F3Held by family trust of which the Reporting Person is a trustee. Shares transferred from Reporting Person to family trust immediately following acquisition.
- F4In accordance with the Company's 2013 Employee Stock Purchase Plan, these shares were purchased based on 85% of the closing price of the Issuer's common stock on November 14, 2017, which was the last trading day of the applicable offering period.
- F5The option was granted on February 4, 2018. 25% of the total number of shares of common stock subject to the option will vest on February 2, 2019, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.